Balaxi Pharmaceuticals Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 806.81 million compared to INR 890.99 million a year ago. Revenue was INR 804.61 million compared to INR 931.66 million a year ago. Net income was INR 81 million compared to INR 127.11 million a year ago. Basic earnings per share from continuing operations was INR 8.01 compared to INR 12.71 a year ago. Diluted earnings per share from continuing operations was INR 7.86 compared to INR 12.71 a year ago.
For the full year, sales was INR 3,364.33 million compared to INR 2,793.88 million a year ago. Revenue was INR 3,390.7 million compared to INR 2,843.6 million a year ago. Net income was INR 459.63 million compared to INR 476.58 million a year ago. Basic earnings per share from continuing operations was INR 45.81 compared to INR 47.66 a year ago. Diluted earnings per share from continuing operations was INR 45.4 compared to INR 47.66 a year ago.